key: cord-0826883-uztwomwb
authors: Sung, Pei-Shan; Yang, Shao-Ping; Peng, Yu-Chun; Sun, Cheng-Pu; Tao, Mi-Hwa; Hsieh, Shie-Liang
title: CLEC5A and TLR2 are critical in SARS-CoV-2-induced NET formation and lung inflammation
date: 2022-02-02
journal: bioRxiv
DOI: 10.1101/2022.02.01.478701
sha: 07e17831030fc621db38fd3f5a58974e9788c9dd
doc_id: 826883
cord_uid: uztwomwb

Coronavirus-induced disease 19 (COVID-19) infects more than three hundred and sixty million patients worldwide, and people with severe symptoms frequently die of acute respiratory distress syndrome (ARDS). Autopsy demonstrates the presence of thrombosis and microangiopathy in the small vessels and capillaries. Recent studies indicated that excessive neutrophil extracellular traps (NETs) contributed to immunothrombosis, thereby leading to extensive intravascular coagulopathy and multiple organ dysfunction. Thus, understanding the mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced NET formation would be helpful to reduce thrombosis and prevent ARDS. It has been shown that sera from individuals with COVID-19 triggered NET release in vitro, and spleen tyrosine kinase (Syk) inhibitor R406 inhibited NETosis caused by COVID-19 plasma. However, the serum components responsible for NET formation are still unknown. In this study, we found that virus-free extracellular vesicles (EVs) from COVID-19 patients (COVID-19 EVs) induced robust NET formation via Syk-coupled C-type lectin member 5A (CLEC5A). Blockade of CLEC5A inhibited COVID-19 EVs-induced NETosis, and simultaneous blockade of CLEC5A and TLR2 further suppressed SARS-CoV-2-induced NETosis in vitro. Moreover, thromboinflammation and lung fibrosis were attenuated dramatically in clec5a-/-/tlr2-/- mice. These results suggest that COVID-19 EVs play critical roles in SARS-CoV-2-induced immunothrombosis, and blockade of CLEC5A and TLR2 is a promising strategy to inhibit SARS-CoV-2-induced intravascular coagulopathy and reduce the risk of ARDS in COVID-19 patients.

CLEC5A and TLR2 to release proinflammatory cytokines and promote NET formation. 81 Moreover, DV activates Syk-coupled C-type lectin member 2 (CLEC2) in platelets to release 82 EVs to enhance DV-induced NET formation and macrophage activation via CLEC5A and 83 TLR2 [25, 26] . Recently, SARS-CoV-2 spike protein was reported to induce NETosis in Syk-84 dependent manner [27] , suggesting that C-type lectins might play important roles in SARS- 85 CoV-2-induced NET formation. Moreover, TLR2 was shown to sense SARS-CoV-2 86 membrane protein to activate NF-kB in monocyte and macrophages [28, 29] . Because 87 CLEC5A and TLR2 are associated and co-activated by platelet-derived EVs (PLT-EVs) [25] , 88 we asked whether CLEC5A and TLR2 also contributed to SARS-CoV-2-induced 89 immunothrombosis. Isolation of mouse primary neutrophils and platelets 138 139 Platelets-rich plasma from murine peripheral blood was collected into ACD-containing 140 Eppendorf and centrifugated at 230 × g for 4 min. Platelets were washed once and harvested 141 by centrifugation at 1000 × g for 4 min, pellet was suspended in Tyrode's buffer. For 142 neutrophil isolation, bone marrow was collected and incubated with RBC lysis buffer. Bone 143 marrow cells were suspended in a 45 % Percoll solution, then laid on 52 %, 63 %, and 81 % 144 Percoll, and were further centrifugated at 1000 × g for 30 min. Neutrophils were harvested from 145 layer 3 of the Percoll gradient, followed by washing with HBSS twice before being suspended 146 in RPMI containing 10 % FBS. The pseudotyped lentivirus carrying the SARS-Co-2 spike protein was generated as described 156 previously [30] . In brief, HEK-293T cells were transiently transfected with 157 pLAS2w.Fluc.Ppuro, pcDNA3.1-2019-nCoV-S, and pCMV-△ R8.91 using TransITR-LT1 158 transfection reagent (Mirus). Cell debris was removed by centrifugation at 4,000×g for 10 min, 159 followed by passing the supernatant through a 0.45 m syringe filter (Pall Corporation). For 160 pseudotyped virus purification and concentration, supernatant was mixed with 0.2 volume of 161 50 % PEG 8,000 (Sigma) and incubated at 4 °C for 2 h. The pseudotyped lentivirus was then recovered by centrifugation at 5,000×g for 2 h, and resuspended in sterilized phosphatebuffered saline, aliquoted, and stored at -80 °C. 164 165 Mouse model for SARS-CoV-2 infection 166 Virus preparation and inoculation of SARS-CoV-2 into C57BL/6 and clec5a -/-/tlr2 -/mice were as 167 described [31] . Lung tissue was collected at 3 days and 5 days post-infection for further analysis. 168 All the animal experiments followed the protocol approved by the Institutional Animal Care and 169 Use Committee (IACUC) at AS core (protocol ID 20-10-1521 Plasma from healthy donors and COVID-19 patients with severe pneumonia were centrifugated at 203 3500 × g for 15 min to remove cells and debris. Supernatants were further centrifuged at 204 100,000 × g for 1.5 h at 4 °C. Pellets were washed with saline and centrifuged at 100,000 × g 205 for 1.5 h at 4 °C, followed by resuspension in 1 ml of saline. The protein concentration of EVs 206 was determined by DC protein assay (Bio-Rad) according to the manufacturer's instruction. Human neutrophils (4×10 5 /ml) were seeded on poly-L-lysine-coated 12 mm coverslip in 24 211 well and simultaneously incubated with SARS-CoV-2 (MOI=0.1 or 1) in presence of 212 autologous platelets (4 × 10 6 /ml) for 5 or 20 h at 37 °C. For SARS-CoV-2-spike pseudotyped virus 213 stimulation, human neutrophils (4×10 5 /ml) were incubated with SARS-CoV-2-spike 214 pseudotyped virus (MOI=0.25) and co-incubated with autologous platelets (4 × 10 6 /ml) for 3 h 215 at 37 °C. For blocking assay, neutrophils were preincubated with isotype (100 g/ml), anti-216 CLEC5A mAb (100 g/ml, clone 3E12A2), anti-TLR2 mAb (100 g/ml, R&D system), or a 217 mixture of anti-CLEC5A mAb and anti-TLR2 mAb for 30 min at room temperature before 218 incubation with SARS-CoV-2. For EVs stimulation assay, neutrophil was incubated with EVs 219 from the plasma of healthy controls (HC-EVs) or COVID-19 EVs for 3 h at 37 °C. We further incubated SARS-CoV-2 and SARS-CoV-2 plus platelets (SARS-CoV-2/platelets) 266 with wild-type (WT) and clec5a -/-tlr2 -/neutrophils, respectivley, in the absence (left, Fig. 1d ) 267 or presence of WT platelets (right, Fig. 1d ). We found that SARS-CoV-2 and SARS-CoV-268 2/platelets-induced NET formation was partially attenuated in clec5a -/neutrophils and tlr2 -/-neutrophils, while NET formation was almost undetectable in clec5a -/-tlr2 -/neutrophils. This 

As COVID-19 sera was reported to induce NET formation [19] , and serum levels of platelet-285 derived EVs (PLT-EVs) correlated with disease severity [18], we asked whether COVID-19 286 EVs induced NET formation was via CLEC5A and TLR2. Firstly, we compared the protein 287 components of EVs isolated from serum samples of COVID-19 patients (COVID-19 EVs) 288 and normal individuals (HC-EVs) by mass spectrometry, and data were analyzed by 'Ingenuity 289 Pathway Analysis' (IPA, QIAGEN) software. We found that molecules involved in platelet 290 degranulation (CD9, platelet factor 4 (PF4)), aggregation, and activation [CD9, CLEC1B (also 291 known as CLEC2)] were upregulated dramatically in COVID-19 EVs, while none of these 292 proteins were detectable in EVs from healthy donors (Fig. 2a) . In addition to these upregulated 293 molecules, proteins specifically expressed in COVID-19 EVs were listed in Table I . We 294 further confirmed the IPA results by flow cytometry analysis. We found that platelet activation 295 markers (CD41a/b, CD62p), integrins (CD9, CD29, CD49e), adhesion molecules (CD31), and 296 other activation marker (CD45, CD69) were upregulated (Fig. 2b & 2c) . We then incubated 297 neutrophils with HC-EVs and COVID-19 EVs, respectively, to compare their abilities to 298 induce NET formation. While EVs from healthy control were unable to induce NET 299 formation, COVID-19 EVs induced robust NET formation, which was blocked efficiently by 300 anti-CLEC5A mAb, but not anti-TLR2 mAb (Fig. 2d) . This observation suggests that COVID-301 19 EVs have potent activity to induce NET formation via CLEC5A. 302 303 CLEC5A and TLR2 are critical in SARS-CoV-2-induced thromboinflammation 304 We have used recombinant adeno-associated virus to introduce human ACE2 (hACE2) into 305 wild type mice to establish a SARS-CoV-2 infection model system [31] . To evaluate the roles 306 of CLEC5A and TLR2 in SARS-CoV-2-induced thromboinflammation, the AAV-hACE2 was 307 introduced to wild-type littermates (WT) and clec5a -/-tlr2 -/mice to address this question. In 308 WT mice, SARS-CoV-2 upregulated the expression of IL-6, IFN-, CCL-2, and IP-10 309 dramatically (more than 10 folds), while TNF-, IL-1, I L-10, and chemokines (CXCL1, 310 CXCL2, CXCL5) were also upregulated (Fig. 3a) . Compared to WT mice, the expression of 

It has been shown that lung is responsible for 50 % of platelet biogenesis or 10 million platelets 349 per hour [33] . Moreover, platelets were hyperactivated in clinically ill 350 13], and contributed to coagulopathy in COVID-19 patients [17] . Thus, we are interested to 351 understand the mechanism of platelet-mediated immunothrombosis in SARS-CoV-2 infection. 352 In this study, we demonstrated that platelets enhanced SARS-CoV-2-induced NET formation 353 ( Supplementary Fig. 1) It has been reported that clinical symptoms, laboratory features and autopsy findings between 389 dengue fever and COVID-19 are similar and are difficult to distinguish, and some patients who software and presented as area (m 2 ). Data are mean ± SEM. ***p < 0.001 (Student's t-test). 460 Data are mean ± SEM. ***p < 0.001 (Student's t-test). N=3 of each group. 

A Novel Coronavirus from Patients with Pneumonia in China

Clinical features of patients infected with 2019 novel coronavirus in 12

Platelets Can Associate with SARS-Cov-2 RNA and Are Hyperactivated 540 in COVID-19

Neutrophil extracellular traps contribute to immunothrombosis in 542

COVID-19 acute respiratory distress syndrome

Endothelial dysfunction and immunothrombosis as key 544 pathogenic mechanisms in COVID-19

Immunothrombosis in COVID-19: Implications of Neutrophil

Circulating Platelet-Derived Extracellular Vesicles Are a 550 Hallmark of Sars-Cov-2 Infection. Cells

Neutrophil extracellular traps in COVID-19

CLEC5A is critical for dengue-virus-induced lethal disease

CLEC5A is critical for dengue virus-induced inflammasome activation 555 in human macrophages

CLEC5A is critical for dengue virus-induced osteoclast activation 557 and bone homeostasis

CLEC5A: A Promiscuous Pattern Recognition 559 Receptor to Microbes and Beyond

CLEC5A is a critical receptor in innate immunity against Listeria 561 infection

Extracellular vesicles from CLEC2-activated 563 platelets enhance dengue virus-induced lethality via CLEC5A/TLR2

C-type lectins and extracellular vesicles in virus

Lectins enhance SARS-CoV-2 infection and influence neutralizing 601 antibodies

SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells 603 through C-type lectin receptors and Tweety family member 2. Immunity

Dengue Virus Infection Is through a Cooperative Interaction between a 606

Mannose Receptor and CLEC5A on Macrophage as a Multivalent Hetero-Complex

Covert COVID-19 and false-positive dengue serology in Singapore

Megakaryocytes and platelet-fibrin thrombi characterize multi-611 organ thrombosis at autopsy in COVID-19: A case series. EClinicalMedicine